In the war on terror, who is it that we’re really fighting? “Caliphate” follows Rukmini Callimachi, who covers terrorism for The New York Times, on her quest to understand ISIS. For more information about the series, visit nytimes.com/caliphate. This series includes disturbing language and scenes of graphic violence. Producer: Andy Mills; Reporters: Rukmini Callimachi and Andy Mills; Managing Producer: Larissa Anderson; Editors: Wendy Dorr and Larissa Anderson; Associate Producer: Asthaa Cha ...
…
continue reading
Content provided by Pharma and BioTech News and BioTech News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Pharma and BioTech News and BioTech News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Pharma and Biotech Daily: Novartis Acquires Tourmaline for $1.4 Billion and Biogen Prepares to Release New Lupus Data
MP3•Episode home
Manage episode 505491050 series 3478766
Content provided by Pharma and BioTech News and BioTech News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Pharma and BioTech News and BioTech News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. Novartis recently acquired Tourmaline for $1.4 billion, continuing its investment in cardiovascular treatments. The company has also made other partnerships in the cardiovascular space this year. Biogen is preparing to release new data on its lupus treatments, with analysts praising the company's pipeline. Novartis has been active in mergers and acquisitions, putting over $17 billion into deals this year. The biotech industry is also seeing some activity, with LB filing for a $228 million IPO to support its phase III plans. Overall, companies like Novartis and Biogen are focusing on expanding their portfolios and developing innovative treatments for various diseases.
…
continue reading
74 episodes
MP3•Episode home
Manage episode 505491050 series 3478766
Content provided by Pharma and BioTech News and BioTech News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Pharma and BioTech News and BioTech News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. Novartis recently acquired Tourmaline for $1.4 billion, continuing its investment in cardiovascular treatments. The company has also made other partnerships in the cardiovascular space this year. Biogen is preparing to release new data on its lupus treatments, with analysts praising the company's pipeline. Novartis has been active in mergers and acquisitions, putting over $17 billion into deals this year. The biotech industry is also seeing some activity, with LB filing for a $228 million IPO to support its phase III plans. Overall, companies like Novartis and Biogen are focusing on expanding their portfolios and developing innovative treatments for various diseases.
…
continue reading
74 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.